<DOC>
	<DOCNO>NCT01815827</DOCNO>
	<brief_summary>This open-label , parallel group study evaluate safety , tolerability , pharmacokinetics pharmacodynamics single dos inclacumab Japanese healthy volunteer compare Caucasian healthy volunteer . Subjects receive single intravenous dose inclacumab . Follow-up 197 day .</brief_summary>
	<brief_title>A Study Single Dose Inclacumab Japanese Healthy Volunteers Compared Caucasian Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 18 55 year age , inclusive Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Japanese subject must Japanese parent grandparent born Japan Caucasian subject must Caucasian parent grandparent Body mass index ( BMI ) 18 30 kg/m2 inclusive Clinically significant abnormality laboratory test result ( include positive test HIV , hepatitis B and/or C ) , vital sign ECGs Any confirm significant allergic reaction drug , multiple allergy ( nonactive hay fever acceptable ) Smokes 5 cigarette per day three month prior study conduct Participation investigational drug device study within 30 day 5 halflives prior screen Positive test drug abuse Any suspicion history alcohol and/or substance abuse addiction Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>